COVID-19 in Cancer Patients
Phase of Development |
Phase 1/2 |
Status |
Recruiting |
Number of Subjects |
Up to 64 |
Study Drug |
Ampligen® and IFN alpha-2b |
Primary Endpoint |
Incidence of AEs, Kinetics of Viral Load |
Study Partner |
Roswell Park |
Clinical Trials NCT # |
NCT04379518 |